Michael Burkes Brophy Sells 946 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 946 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $171.98, for a total value of $162,693.08. Following the completion of the transaction, the chief financial officer now owns 109,474 shares of the company’s stock, valued at $18,827,338.52. This trade represents a 0.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07.
• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The stock was sold at an average price of $126.45, for a total transaction of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $118.21, for a total transaction of $146,343.98.

Natera Trading Down 2.5 %

Shares of Natera stock opened at $167.61 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock’s 50 day simple moving average is $166.20 and its 200-day simple moving average is $136.25. The stock has a market cap of $22.13 billion, a P/E ratio of -95.23 and a beta of 1.65. Natera, Inc. has a 1-year low of $62.96 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business’s revenue for the quarter was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.95) EPS. Analysts predict that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently modified their holdings of NTRA. Blue Trust Inc. boosted its stake in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the period. Quarry LP lifted its holdings in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares during the last quarter. Versant Capital Management Inc boosted its position in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the period. Covestor Ltd boosted its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. Finally, GAMMA Investing LLC increased its holdings in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of recent research reports. Sanford C. Bernstein lifted their price objective on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. JPMorgan Chase & Co. raised their target price on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. The Goldman Sachs Group raised their price objective on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Finally, Morgan Stanley upped their target price on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $162.94.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.